Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

Abstract The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is a single-arm, phase II trial that recruited chemother...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, Paula Jimenez-Fonseca, Alex Teule, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso-Gordoa, Ana Custodio, Beatriz Anton-Pascual, Jorge Hernando, Eduardo Polo, Oscar Alfredo Castillo-Trujillo, Arantza Lamas-Paz, Ana Teijo, Yolanda Rodriguez-Gil, Beatriz Soldevilla, Rocio Garcia-Carbonero
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2024-08-01
סדרה:	Nature Communications
גישה מקוונת:	https://doi.org/10.1038/s41467-024-50969-8
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!